Company news

Enveric Biosciences, Inc. news in 2021

Enveric Biosciences, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Enveric Biosciences Appoints Dr. Bob Dagher as Chief Medical Officer

December 5, 2021

Enveric Biosciences Announces Positive Preclinical Data for EV102 Radiodermatitis Drug Candidate

November 17, 2021

Enveric Biosciences Announces Inclusion in AdvisorShares Psychedelics ETF

November 7, 2021

Enveric Biosciences Announces Artificial Intelligence Platform, PsyAI™, Has Identified Viable Drug Candidates from its 'Psybrary' of Psychedelic Molecular Compounds

October 4, 2021

Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

September 16, 2021

Enveric Biosciences Announces Approval from Israel's Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment for Glioblastoma

July 7, 2021

Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives

May 23, 2021

Enveric Biosciences Reports First Quarter 2021 Financial Results

May 17, 2021

Enveric Biosciences Appoints Dr. Arash Asher to Scientific Advisory Board

May 11, 2021

Enveric Biosciences Appoints Carter Ward as Chief Financial Officer

April 11, 2021

Enveric Biosciences Reports Full Year 2020 Financial Results and Provides Shareholder Update on its Accomplishments in 2021

March 31, 2021

Enveric Biosciences Appoints Dr. Douglas D. Lind to Company's Board of Directors

March 17, 2021

Enveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech

March 9, 2021

Enveric Biosciences Launches Development Collaboration and Supply Agreement with PureForm Global to Support Cannabinoid Clinical Programs

February 24, 2021

Enveric Biosciences Inc. Announces Closing of $12.8 Million Registered Direct Offering of Common Stock

February 11, 2021

Enveric Biosciences Inc. Announces $12.8 Million Registered Direct Offering

February 8, 2021

Enveric Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering

January 14, 2021

Enveric Biosciences Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

January 11, 2021

Enveric Biosciences Appoints Dr. Marcus Schabacker to Board of Directors

January 4, 2021

Decks in 2021